Upregulation of HLA-II related to LAG-3⁺CD4⁺ T cell infiltration is associated with patient outcome in human glioblastoma.

ABSTRACT: Glioblastoma (GBM) is the most common malignant diffuse glioma of the brain. Although immunotherapy with immune checkpoint inhibitors (ICIs), such as programmed cell death protein (PD)-1/PD ligand-1 inhibitors, has revolutionized the treatment of several cancers, the clinical benefit in GBM patients has been limited. Lymphocyte-activation gene 3 (LAG-3) binding to human leukocyte antigen-II (HLA-II) plays an essential role in triggering CD4⁺ T cell exhaustion and could interfere with the efficiency of anti-PD-1 treatment; however, the value of LAG-3-HLA-II interactions in ICI immunotherapy for GBM patients has not yet been analyzed. Therefore, we aimed to investigate the expression and regulation of HLA-II in human GBM samples and the correlation with LAG-3⁺CD4^+<

SUBMITTER: Guo W 

PROVIDER: S-EPMC11093187 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature